Metformin Use Is Associated with Improved Survival in Patients Undergoing Resection for Pancreatic Cancer

Marcelo Cerullo, Faiz Gani, Sophia Y. Chen, Joe Canner, Timothy M. Pawlik

Research output: Contribution to journalArticle

Abstract

Preclinical evidence has demonstrated anti-tumorigenic effects of metformin. The effects of metformin following pancreatic cancer, however, remain undefined. We sought to assess the association between metformin use and survival using a large, nationally representative sample of patients undergoing surgery for pancreatic cancer. Patients undergoing a pancreatic resection between January 01, 2010, and December 31, 2012, were identified using the Truven Health MarketScan database. Clinical data, including history of metformin use, as well as operative details and information on long-term outcomes were collected. Multivariable Cox proportional hazards regression analysis was performed to assess the effect of metformin use on overall survival (OS). A total of 3393 patients were identified. The mean age of patients was 54.2 years (SD = 9.1 years). Roughly one half of patients were female (n = 1735, 51.1 %); 49.1 % (n = 1665) presented with a Charlson comorbidity index of 3 or greater (CCI ≥3); and 19.6 % (n = 664) had diabetes. At the time of surgery, 60.0 % (n = 2034) of patients underwent a pancreaticoduodenectomy, 35.7 % (n = 1212) a partial/distal pancreatectomy, while 4.3 % (n = 147) had a total pancreatectomy. On pathology, 1057 (31.2 %) had lymph node metastasis. Metformin use was identified in 456 patients (13.4 %) and was more commonly administered among patients without locally advanced disease (14.3 vs. 11.6 %, p = 0.038). While OS was comparable between patients within the first year of surgery (OS at 1 year 65.4 % [95 % confidence interval (CI) 63.4–67.3 %] vs. 69.2 % [95 % CI 64.2–73.4 %]), patients who received metformin demonstrated an improved OS beginning at 18 months following surgery. On multivariable analysis adjusting for patient and clinicopathologic characteristics, metformin use was independently associated with a decreased risk of mortality (hazard ratio [HR] = 0.79, 95 % CI 0.67–0.93, p = 0.005). Metformin use was associated with an improved overall survival among patients undergoing pancreatic surgery for pancreatic cancer. Further work is necessary to better understand its role in modifying cancer-specific and overall health outcomes.

Original languageEnglish (US)
Pages (from-to)1572-1580
Number of pages9
JournalJournal of Gastrointestinal Surgery
Volume20
Issue number9
DOIs
StatePublished - Sep 1 2016

Fingerprint

Metformin
Pancreatic Neoplasms
Survival
Pancreatectomy
Confidence Intervals
Patient Advocacy
Pancreaticoduodenectomy
Health
Comorbidity
Lymph Nodes
Regression Analysis
Databases
Pathology
Neoplasm Metastasis

Keywords

  • Metformin
  • Pancreatic cancer
  • Survival post-surgery

ASJC Scopus subject areas

  • Surgery
  • Medicine(all)
  • Gastroenterology

Cite this

Metformin Use Is Associated with Improved Survival in Patients Undergoing Resection for Pancreatic Cancer. / Cerullo, Marcelo; Gani, Faiz; Chen, Sophia Y.; Canner, Joe; Pawlik, Timothy M.

In: Journal of Gastrointestinal Surgery, Vol. 20, No. 9, 01.09.2016, p. 1572-1580.

Research output: Contribution to journalArticle

Cerullo, Marcelo ; Gani, Faiz ; Chen, Sophia Y. ; Canner, Joe ; Pawlik, Timothy M. / Metformin Use Is Associated with Improved Survival in Patients Undergoing Resection for Pancreatic Cancer. In: Journal of Gastrointestinal Surgery. 2016 ; Vol. 20, No. 9. pp. 1572-1580.
@article{9648fb3bc6344c519c518cb01368e6de,
title = "Metformin Use Is Associated with Improved Survival in Patients Undergoing Resection for Pancreatic Cancer",
abstract = "Preclinical evidence has demonstrated anti-tumorigenic effects of metformin. The effects of metformin following pancreatic cancer, however, remain undefined. We sought to assess the association between metformin use and survival using a large, nationally representative sample of patients undergoing surgery for pancreatic cancer. Patients undergoing a pancreatic resection between January 01, 2010, and December 31, 2012, were identified using the Truven Health MarketScan database. Clinical data, including history of metformin use, as well as operative details and information on long-term outcomes were collected. Multivariable Cox proportional hazards regression analysis was performed to assess the effect of metformin use on overall survival (OS). A total of 3393 patients were identified. The mean age of patients was 54.2 years (SD = 9.1 years). Roughly one half of patients were female (n = 1735, 51.1 {\%}); 49.1 {\%} (n = 1665) presented with a Charlson comorbidity index of 3 or greater (CCI ≥3); and 19.6 {\%} (n = 664) had diabetes. At the time of surgery, 60.0 {\%} (n = 2034) of patients underwent a pancreaticoduodenectomy, 35.7 {\%} (n = 1212) a partial/distal pancreatectomy, while 4.3 {\%} (n = 147) had a total pancreatectomy. On pathology, 1057 (31.2 {\%}) had lymph node metastasis. Metformin use was identified in 456 patients (13.4 {\%}) and was more commonly administered among patients without locally advanced disease (14.3 vs. 11.6 {\%}, p = 0.038). While OS was comparable between patients within the first year of surgery (OS at 1 year 65.4 {\%} [95 {\%} confidence interval (CI) 63.4–67.3 {\%}] vs. 69.2 {\%} [95 {\%} CI 64.2–73.4 {\%}]), patients who received metformin demonstrated an improved OS beginning at 18 months following surgery. On multivariable analysis adjusting for patient and clinicopathologic characteristics, metformin use was independently associated with a decreased risk of mortality (hazard ratio [HR] = 0.79, 95 {\%} CI 0.67–0.93, p = 0.005). Metformin use was associated with an improved overall survival among patients undergoing pancreatic surgery for pancreatic cancer. Further work is necessary to better understand its role in modifying cancer-specific and overall health outcomes.",
keywords = "Metformin, Pancreatic cancer, Survival post-surgery",
author = "Marcelo Cerullo and Faiz Gani and Chen, {Sophia Y.} and Joe Canner and Pawlik, {Timothy M.}",
year = "2016",
month = "9",
day = "1",
doi = "10.1007/s11605-016-3173-4",
language = "English (US)",
volume = "20",
pages = "1572--1580",
journal = "Journal of Gastrointestinal Surgery",
issn = "1091-255X",
publisher = "Springer New York",
number = "9",

}

TY - JOUR

T1 - Metformin Use Is Associated with Improved Survival in Patients Undergoing Resection for Pancreatic Cancer

AU - Cerullo, Marcelo

AU - Gani, Faiz

AU - Chen, Sophia Y.

AU - Canner, Joe

AU - Pawlik, Timothy M.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Preclinical evidence has demonstrated anti-tumorigenic effects of metformin. The effects of metformin following pancreatic cancer, however, remain undefined. We sought to assess the association between metformin use and survival using a large, nationally representative sample of patients undergoing surgery for pancreatic cancer. Patients undergoing a pancreatic resection between January 01, 2010, and December 31, 2012, were identified using the Truven Health MarketScan database. Clinical data, including history of metformin use, as well as operative details and information on long-term outcomes were collected. Multivariable Cox proportional hazards regression analysis was performed to assess the effect of metformin use on overall survival (OS). A total of 3393 patients were identified. The mean age of patients was 54.2 years (SD = 9.1 years). Roughly one half of patients were female (n = 1735, 51.1 %); 49.1 % (n = 1665) presented with a Charlson comorbidity index of 3 or greater (CCI ≥3); and 19.6 % (n = 664) had diabetes. At the time of surgery, 60.0 % (n = 2034) of patients underwent a pancreaticoduodenectomy, 35.7 % (n = 1212) a partial/distal pancreatectomy, while 4.3 % (n = 147) had a total pancreatectomy. On pathology, 1057 (31.2 %) had lymph node metastasis. Metformin use was identified in 456 patients (13.4 %) and was more commonly administered among patients without locally advanced disease (14.3 vs. 11.6 %, p = 0.038). While OS was comparable between patients within the first year of surgery (OS at 1 year 65.4 % [95 % confidence interval (CI) 63.4–67.3 %] vs. 69.2 % [95 % CI 64.2–73.4 %]), patients who received metformin demonstrated an improved OS beginning at 18 months following surgery. On multivariable analysis adjusting for patient and clinicopathologic characteristics, metformin use was independently associated with a decreased risk of mortality (hazard ratio [HR] = 0.79, 95 % CI 0.67–0.93, p = 0.005). Metformin use was associated with an improved overall survival among patients undergoing pancreatic surgery for pancreatic cancer. Further work is necessary to better understand its role in modifying cancer-specific and overall health outcomes.

AB - Preclinical evidence has demonstrated anti-tumorigenic effects of metformin. The effects of metformin following pancreatic cancer, however, remain undefined. We sought to assess the association between metformin use and survival using a large, nationally representative sample of patients undergoing surgery for pancreatic cancer. Patients undergoing a pancreatic resection between January 01, 2010, and December 31, 2012, were identified using the Truven Health MarketScan database. Clinical data, including history of metformin use, as well as operative details and information on long-term outcomes were collected. Multivariable Cox proportional hazards regression analysis was performed to assess the effect of metformin use on overall survival (OS). A total of 3393 patients were identified. The mean age of patients was 54.2 years (SD = 9.1 years). Roughly one half of patients were female (n = 1735, 51.1 %); 49.1 % (n = 1665) presented with a Charlson comorbidity index of 3 or greater (CCI ≥3); and 19.6 % (n = 664) had diabetes. At the time of surgery, 60.0 % (n = 2034) of patients underwent a pancreaticoduodenectomy, 35.7 % (n = 1212) a partial/distal pancreatectomy, while 4.3 % (n = 147) had a total pancreatectomy. On pathology, 1057 (31.2 %) had lymph node metastasis. Metformin use was identified in 456 patients (13.4 %) and was more commonly administered among patients without locally advanced disease (14.3 vs. 11.6 %, p = 0.038). While OS was comparable between patients within the first year of surgery (OS at 1 year 65.4 % [95 % confidence interval (CI) 63.4–67.3 %] vs. 69.2 % [95 % CI 64.2–73.4 %]), patients who received metformin demonstrated an improved OS beginning at 18 months following surgery. On multivariable analysis adjusting for patient and clinicopathologic characteristics, metformin use was independently associated with a decreased risk of mortality (hazard ratio [HR] = 0.79, 95 % CI 0.67–0.93, p = 0.005). Metformin use was associated with an improved overall survival among patients undergoing pancreatic surgery for pancreatic cancer. Further work is necessary to better understand its role in modifying cancer-specific and overall health outcomes.

KW - Metformin

KW - Pancreatic cancer

KW - Survival post-surgery

UR - http://www.scopus.com/inward/record.url?scp=84982295013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982295013&partnerID=8YFLogxK

U2 - 10.1007/s11605-016-3173-4

DO - 10.1007/s11605-016-3173-4

M3 - Article

VL - 20

SP - 1572

EP - 1580

JO - Journal of Gastrointestinal Surgery

JF - Journal of Gastrointestinal Surgery

SN - 1091-255X

IS - 9

ER -